Shwu-Huey Liu
Overview
Explore the profile of Shwu-Huey Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
665
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Verma N, Johung K, Kortmansky J, Zaheer W, Lacy J, Cecchini M, et al.
J Gastrointest Oncol
. 2024 Jul;
15(3):1050-1059.
PMID: 38989411
Background: Pre-operative chemoradiation for rectal cancer is often associated with severe gastrointestinal (GI) toxicity which can interrupt, delay, and/or lead to termination of treatment. In this study, we evaluated whether...
2.
Lam W, Arammash M, Cai W, Guan F, Jiang Z, Liu S, et al.
Front Pharmacol
. 2023 Oct;
14:1244655.
PMID: 37860121
Prostate cancer is the second leading cause of cancer death among men in the United States. Castration-Resistant Prostate Cancer (CRPC) often develops resistance to androgen deprivation therapy. Resistance in CRPC...
3.
Lam W, Hu R, Liu S, Cheng P, Cheng Y
Front Pharmacol
. 2023 Jan;
13:1095186.
PMID: 36686648
YIV-906 is a systems biology botanical cancer drug, inspired by a traditional Chinese herbal formulation. Results from eight Phase I/II to II clinical studies demonstrated the potential of YIV-906 to...
4.
Yang X, Lam W, Jiang Z, Guan F, Han X, Hu R, et al.
Sci Rep
. 2021 Jun;
11(1):13482.
PMID: 34188068
YIV-906 (PHY906) is a standardized botanical cancer drug candidate developed with a systems biology approach-inspired by a traditional Chinese herbal formulation, historically used to treat gastrointestinal symptoms including diarrhea, nausea...
5.
Changou C, Shiah H, Chen L, Liu S, Luh F, Liu S, et al.
Oncologist
. 2020 Nov;
26(3):e367-e373.
PMID: 33140457
Lessons Learned: A PHY906 and capecitabine combination could be effective as a salvage therapy for patients with hepatocellular carcinoma (HCC) previously treated with multiple systemic therapies. This traditional Chinese medicine...
6.
Lam W, Ren Y, Guan F, Jiang Z, Cheng W, Xu C, et al.
Front Pharmacol
. 2018 Dec;
9:1324.
PMID: 30510512
YIV-906 (PHY906), a four-herb Chinese medicine formulation, is inspired by an 1800 year-old Chinese formulation called Huang Qin Tang which is traditionally used to treat gastrointestinal (GI) symptoms. In animal...
7.
Lam W, Jiang Z, Guan F, Huang X, Hu R, Wang J, et al.
Sci Rep
. 2015 Mar;
5:9384.
PMID: 25819872
PHY906 (KD018) is a four-herb Chinese Medicine Formula. It has been shown to potentially enhance the therapeutic indices of different class anticancer agents in vivo. Here, PHY906 is reported to...
8.
Liu S, Chuang W, Lam W, Jiang Z, Cheng Y
Drug Saf
. 2015 Feb;
38(2):117-28.
PMID: 25647717
Herbal medicine, including traditional Chinese medicine, has been used for the prevention, treatment, and cure of disorders or diseases for centuries. In addition to being used directly as therapeutic agents,...
9.
Lam W, Jiang Z, Guan F, Hu R, Liu S, Chu E, et al.
BMC Complement Altern Med
. 2014 Dec;
14:490.
PMID: 25510341
Background: The four-herb Chinese medicine PHY906(KD018) has been shown to both enhance the in vivo antitumor activity of irinotecan (CPT-11) against colon cancer tumor allografts and alleviate intestinal toxicity caused...
10.
Saif M, Li J, Lamb L, Kaley K, Elligers K, Jiang Z, et al.
Cancer Chemother Pharmacol
. 2013 Dec;
73(2):373-80.
PMID: 24297682
Background: Preclinical studies showed a Chinese botanical formula, PHY906, has synergistic anti-tumor activity with capecitabine. Our phase I study determined maximal tolerated dose of capecitabine 1,500 mg/m(2) BID day 1-7...